



Depression Care Process Model (CPM)

- AHC Agency for Health Care, Policy and Research. *Clinical Practice Guidelines for Depression in Primary Care: Treatment of Major Depression, Number 5*. Rockville, MD: U.S. Department of Health and Human Services; Agency for Health Care, Policy and Research; 1993. AHCPR Publication No. 93-0550.
- AHRQ US Department of Health and Human Services. Agency for Healthcare Research and Quality. *Nonpharmacologic Interventions for Treatment-Resistant Depression in Adults — Executive Summary*, September 23, 2011. http://effectivehealthcare.ahrq.gov/ehc/products/76/787/Treatment-Resistant-Depression_executivesummary.pdf. Accessed December 17, 2012.
- ALE Alexopoulos GS, Canuso CM, Gharabawi GM, et al. Placebo-controlled study of relapse prevention with risperidone augmentation in older patients with resistant depression. *Am J Geriatr Psychiatry*. 2008;16(1): 21-30.
- ALO Alonso J, Petukhova M, Vilagut G, et al. Days out of role due to common physical and mental conditions: results from the WHO World Mental Health surveys. *Mol Psychiatry*. 2011;16(12):1234-1246.
- AND Anderson IM. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. *J Affect Disord*. 2000;58(1):19-36.
- AND Anderson JC, McGee R. Comorbidity of depression in children and adolescents. In: Reynolds WM, Johnson HF, eds. *Handbook of Depression in Children and Adolescents*. New York, NY: Plenum Press; 1994:581-601.
- ANG Angold A, Costello EJ. Depressive comorbidity in children and adolescents: empirical, theoretical, and methodological issues. *Am J Psychiatry*. 1993;150(12):1779-1791.
- APA1 American Psychiatric Association. *Practice Guideline for the Treatment of Patients with Major Depressive Disorder, Third Edition*. November 2010. Available at http://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdf. Accessed Dec. 14, 2012.
- APA2 American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition*. Washington, DC: American Psychiatric Association; 2013.
- BAL Balon R. SSRI-associated sexual dysfunction. *Am J Psychiatry*. 2006;163(9):1504-1509.
- BAU Bauer M, Bschor T, Kunz D, Berghöfer A, Ströhle A, Müller-Oerlinghausen B. Double-blind, placebo-controlled trial of the use of lithium to augment antidepressant medication in continuation treatment of unipolar major depression. *Am J Psychiatry*. 2000;157(9):1429-1435.
- BER Berman RM, Marcus RN, Swanink R, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. *J Clin Psychiatry*. 2007;68(6):843-853.
- BIR Birmaher B, Brent D, Bernet W, et al; AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with depressive disorders. *J Am Acad Child Adolesc Psychiatry*. 2007;46(11):1503-1526.
- BOU Bouwer CD, Harvey BH. Phasic craving for carbohydrate observed with citalopram. *Int Clin Psychopharmacol*. 1996;11(4):273-278.
- CAR Carpenter LL, Yasmin S, Price LH. A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine. *Biol Psychiatry*. 2002;51(2):183-188.
- CDC1 Centers for Disease Control and Prevention. Current depression among adults — United States, 2006 and 2008. *Morbidity and Mortality Weekly Report*. 2010;59(38):1229-1235. <http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5938a2.htm>. Accessed December 14, 2012.
- CDC2 Centers for Disease Control and Prevention. QuickStats: Prevalence of current depression among persons aged ≥ 12 years by age group and sex — United States, National Health and Nutrition Examination Survey, 2007-2010. *Morbidity and Mortality Weekly Report*. 2012;60(51):11741.
- CEP Cepoiu M, McCusker J, Cole MG, Sewitch M, Belzile E, Ciampi A. Recognition of depression by non-psychiatric physicians — a systematic literature review and meta-analysis. *J Gen Intern Med*. 2008;23(1):25-36.
- CRO Crossley NA, Bauer M. Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analyses of randomized, placebo-controlled trials. *J Clin Psychiatry*. 2007;68(6):935-940.
- DAT Datto C, Lam RW, Lepola U, et al. *Double-blind Study of Extended Release Quetiapine Fumarate (XR) Monotherapy for Maintenance Treatment of Major Depressive Disorder*. Poster presented at: 116th Annual American Psychiatric Association Meeting; August 14-17, 2008; Boston, MA.
- DAV Davis R, Wilde MI. Mirtazapine: A review of its pharmacology and therapeutic potential in the management of major depression. *CNS Drugs*. 1996;5(5):389-402.
- DEG de Groot JC, de Leeuw FE, Oudkerk M, Hofman A, Jolles J, Breteler MM. Cerebral white matter lesions and depressive symptoms in elderly adults. *Arch Gen Psychiatry*. 2000;57(11):1071-1076.
- DEW Dew MA, Whyte EM, Lenze EJ, et al. Recovery from major depression in older adults receiving augmentation of antidepressant pharmacotherapy. *Am J Psychiatry*. 2007;64(6):892-899.
- DOU Doughty MJ, Lyle WM. Medications used to prevent migraine headaches and their potential ocular adverse effects. *Optom Vis Sci*. 1995;72(12):879-891.
- DRU Druss BG, Schlesinger M, Allen HM Jr. Depressive symptoms, satisfaction with health care, and 2-year work outcomes in an employed population. *Am J Psychiatry*. 2001;158(5):731-734.
- EAT Eaton DK, Kann L, Kinchen S, et al. Youth Risk Behavior Surveillance — United States, 2009. *Morbidity and Mortality Weekly Report*. 2010;59(SS05):1-142. <http://www.cdc.gov/MMWR/Preview/MMWRhtml/ss5905a1.htm>. Accessed October 31, 2016.
- ELK El-Khalili N, Joyce M, Atkinson S, et al. *Adjunctive ER Quetiapine Fumarate (XR) in Patients with Major Depressive Disorder and Inadequate Antidepressant Response*. Poster presented at: 116th Annual American Psychiatric Association Meeting; August 14-17, 2008; Boston, MA.
- FAV Fava M. Augmentation and combination strategies in treatment-resistant depression. *J Clin Psychiatry*. 2001;62(suppl 18):4-11.
- FDA1 U.S. Food and Drug Administration. *FDA Public Health Advisory: Reports of Suicidality in Pediatric Patients Being Treated with Antidepressant Medications for Major Depressive Disorder (MDD)*. <http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm168828.htm>. Accessed December 17, 2012.
- FDA2 U.S. Food and Drug Administration. *Questions and Answers on Antidepressant Use in Children, Adolescents, and Adults*. <http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm096321.htm>. Accessed December 17, 2012.

REFERENCE LIST: Depression Care Process Model (CPM)

- FDA3 U.S. Food and Drug Administration. *Antidepressant Use in Children, Adolescents, and Adults*. <http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm096273.htm>. Accessed December 17, 2012.
- FDA4 U.S. Food and Drug Administration. *Antidepressant Drug Use in Pediatric Populations*. <http://www.fda.gov/NewsEvents/Testimony/ucm113265.htm>. Accessed Dec. 17, 2012.
- FIE Fiedorowicz JG, Endicott J, Leon AC, Solomon DA, Keller MB, Coryell WH. Subthreshold hypomanic symptoms in progression from unipolar major depression to bipolar disorder. *Am J Psychiatry*. 2011;168(1):40-48.
- FLE Fleck MP, Horwath E. Pharmacologic management of difficult-to-treat depression in clinical practice. *Psychiatr Serv*. 2005;56(8):1005-1011.
- FOU Fournier JC, DeRubeis RJ, Hollon SD, et al. Antidepressant drug effects and depression severity: A patient-level meta-analysis. *JAMA*. 2010;303(1):47-53.
- GER Gerber PE, Lynd, LD. Selective serotonin-reuptake inhibitor-induced movement disorders. *Ann Pharmacother*. 1998;32(6):692-698.
- GIL Gill JM, Klinkman MS, Chen YX. Antidepressant medication use for primary care patients with and without medical comorbidities: A national electronic health record (EHR) network study. *J Am Board Fam Med*. 2010;23(4):499-508.
- GRE Greenberg PE, Kessler RC, Birnbaum HG, et al. Economic burden of depression in the United States: How did it change between 1990 and 2000? *J Clin Psychiatry*. 2003;(12)64:1465-1475.
- HAM Hamilton JA, Halbreich U. Special aspects of neuropsychiatric illness in women: With a focus on depression. *Ann Rev Med*. 1993;44:355-364.
- HUN Hunkeler EM, Meresman JF, Hargreaves WA, et al. Efficacy of nurse telehealth care and peer support in augmenting treatment of depression in primary care. *Arch Fam Med*. 2000;9(8):700-708.
- JUD1 Judd LL, Akiskal HS, Master JD, et al. Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse. *J Affect Disord*. 1998;172(2-3):97-108.
- JUD2 Judd L, Paulus M, Schettler P, et al. Does incomplete recovery from first lifetime major depressive episode herald a chronic course of illness? *Am J Psychiatry*. 2000;157(9):1501-1504.
- KAT1 Katon W, Sullivan MD. Depression and chronic medical illness. *J Clin Psychiatry*. 1990;51(Suppl 3):3-11.
- KAT2 Katon W, Schulberg H. Epidemiology of depression in primary care. *Gen Hosp Psychiatry*. 1992;14(4):237-242.
- KES Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age of onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. *Arch Gen Psychiatry* 2005;56(2):593-602.
- KNO Knowler WC, Fowler SE, Hamman RF, et al; Diabetes Prevention Program Research Group. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. *Lancet*. 2009;374(9702):1677-1686.
- KOS Koszewska I, Rybakowski JK. Antidepressant-induced mood conversions in bipolar disorder: A retrospective study of tricyclic versus non-tricyclic antidepressant drugs. *Neuropsychobiology*. 2009;59(1):12-16.
- KOW Kowatch RA, Fristad M, Birmaher B et al. Treatment guidelines for children and adolescents with bipolar disorder: Child psychiatric workgroup on bipolar disorder. *J Am Acad Child Adolesc Psychiatry*. 2005; 44(3):213-235.
- KRO Kroenke K, Spitzer RL, Williams JB, et al. Physical symptoms in primary care: Predictors of psychiatric disorders and functional impairment. *Arch Fam Med*. 1994;3(9):774-779.
- LEO Leo RJ. Movement disorders associated with the serotonin selective reuptake inhibitors. *J Clin Psychiatry*. 1996;57(10):449-454.
- LEV Leverich GS, Altshuler LL, Frye MA, et al. Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers. *Am J Psychiatry*. 2006;163(2):232-239.
- LEW Lewinsohn PM, Clarke GN, Seeley JR, Rohde P. Major depression in community adolescents: Age at onset, episode duration, and time to recurrence. *J Am Acad Child Adolesc Psychiatry*. 1994;33(6):809-818.
- LIN1 Lin EH, Von Korff M, Katon W, et al. The role of primary care physician in patient's adherence to antidepressant therapy. *Med Care*. 1995;33(1):67-74.
- LIN2 Lin EH, Katon WJ, Von Korff M, et al. Relapse of depression in primary care: rate and clinical predictors. *Arch Fam Med*. 1998;7(5):443-449.
- LIZ Li Z, Maglione M, Tu W, et al. Meta-analysis: Pharmacologic treatment of obesity. *Ann Intern Med*. 2005;142(7):532-546.
- MAR Marcus RN, McQuade RD, Carson WH, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: A second multicenter, randomized, double-blind, placebo-controlled study. *J Clin Psychopharmacol*. 2008;28(2):156-165.
- MAR Marder S, Stroup TS. Pharmacotherapy for schizophrenia: Side effect management. In: *UpToDate*, Stein, M (Ed), UpToDate, Waltham, MA, 2012.
- MIC Michelson D, Amsterdam JD, Quitkin FM, et al. Changes in weight during a one-year trial of fluoxetine. *Am J Psychiatry*. 1999;156(8):1170-1176.
- MOJ Mojtabai R, Olfson M. National patterns in antidepressant treatment by psychiatrists and general medical providers: Results from the national comorbidity survey replication. *J Clin Psychiatry*. 2008;69(7):1064-1074.
- NEL Nelson JC. Managing treatment-resistant major depression. *J Clin Psychiatry*. 2003;64(suppl 1):5-12.
- NOO Noorani NH and Montagnini M. Recognizing depression in palliative care patients. *Journal of Palliative Care Medicine*. 2007;10(2):458-464.
- OLF Olfson M, Shaffer D, Marcus SC, Greenberg T. Relationship between antidepressant medication treatment and suicide in adolescents. *Arch Gen Psychiatry*. 2003;60(10):978-982.
- OST Ostroff RB, Nelson JC. Risperidone augmentation of selective serotonin reuptake inhibitors in major depression. *J Clin Psychiatry*. 1999; 60(4):256-259.
- PAR Parikh S, Lam R; CANMAT Depression Work Group. Clinical guidelines for the treatment of depressive disorders. *Can J Psychiatry*. 2001; 46(suppl 1):13S-20S.
- PAY Paykel ES, Ramana R, Cooper Z, Hayhurst H, Kerr J, Barocka A. Residual symptoms after partial remission: An important outcome in depression. *Psychol Med*. 1995;25(6):1171-1180.
- PEL Pelkonen M, Marttunen M. Child and adolescent suicide: Epidemiology, risk factors, and approaches to prevention. *Paediatr Drugs*. 2003;5(4):243-265.
- PER1 Perlis RH, Brown E, Baker RW, Nierenberg AA. Clinical features of bipolar depression versus major depressive disorder in large multicenter trials. *Am J Psychiatry*. 2006;163(2):225-231.
- PER2 Peritogiannis V, Antoniou K, Mouka V, Mavreas V, Hyphantis TN. Duloxetine-induced hypomania: Case report and brief review of the literature on SNRIs-induced mood switching. *J Psychopharmacol*. 2009;23(5):592-596.
- PIN Pincus HA, Zarin DA, Tanielian TL, et al. Psychiatric patients and treatments in 1997: Findings from the American Psychiatric Practice Research Network. *Arch Gen Psychiatry*. 1999;56(5):442-449.

REFERENCE LIST: Depression Care Process Model (CPM)

- PRA Prager LM. Depression and suicide in children and adolescents. *Pediatr Rev.* 2009;30(6):199-205.
- REI Reiss-Brennan B, Briot PC, Savitz LA, Cannon W, Staheli R. Cost and quality impact of Intermountain's mental health integration program. *J Healthc Manag.* 2010;55(2):97-113; discussion 113-114.
- RUS Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report. *Am J Psychiatry.* 2006;163(11):1905-1917.
- SAN Sansone RA, Sansone LA. Antidepressant adherence: Are patients taking their medications? *Innov Clin Neurosci.* 2012;9(5-6):41-46.
- SHE1 Shelton RC, Papakostas GI. Augmentation of antidepressants with atypical antipsychotics for treatment-resistant major depressive disorder. *Acta Psychiatr Scand.* 2008;117(4):253-259.
- SHE2 Shelton RC, Tollefson GD, Tohen M, et al. A novel augmentation strategy for treating resistant major depression. *Am J Psychiatry.* 2001;158(1):131-134.
- SIM Simon G. Long-term prognosis of depression in primary care. *Bull World Health Org.* 2000;78(4):439-435.
- SMI Smith SR, Weissman NJ, Anderson CM, et al; Behavioral Modification and Lorcaserin for Overweight and Obesity Management (BLOOM) Study Group. Multicenter, placebo-controlled trial of lorcaserin for weight management. *N Engl J Med.* 2010;363(3):245-256.
- SNY Snyderman D and Wynn D. Depression in cancer patients. *Primary Care: Clinics in Office Practice.* 2001;36(4):703-719.
- TRI1 Trivedi MH, Lin EH, Katon WJ. Consensus recommendations for improving adherence, self-management, and outcomes in patients with depression. *CNS Spectr.* 2007;12(8 Suppl 13):1-27.
- TRI2 Trivedi MH, Fava M, Wisniewski SR, et al; STAR*D Study Team. Medication augmentation after the failure of SSRIs for depression. *N Engl J Med.* 2006;354(12):1243-1252.
- VAL Valenstein M, McCarthy JF, Austin KL, Greden JF, Young EA, Blow FC. What happened to lithium? Antidepressant augmentation in clinical settings. *Am J Psychiatry.* 2006;163(7):1219-1225.
- VAN Vanelli M, Coca-Perraillon M. Role of patient experience in antidepressant adherence: a retrospective data analysis. *Clin Ther.* 2008;30(9):1737-1745.
- WAL Walker PW, Cole JO, Gardner EA, et al. Improvement in fluoxetine-associated sexual dysfunction in patients switched to bupropion. *J Clin Psychiatry.* 1993;54(12):459-465.
- WAR Warner J. Warning issued for kids taking effexor: Use of antidepressants for childhood depression under scrutiny. <http://www.webmd.com/depression/news/20030904/warning-kids-effexor>. Accessed December 17, 2012.
- WEI Weisler R, Joyce M, McGill L, Lazarus A, Schollin M, Brecher M. *Extended Release Quetiapine Fumarate (XR) Monotherapy for Major Depressive Disorder (MDD): A Double-blind, Placebo-controlled Study.* Poster presented at: 116th Annual American Psychiatric Association Meeting; August 14-17, 2008; Boston, MA.
- WEL Wells K, Sherbourne C, Schoenbaum M, et al. Impact of disseminating quality improvement programs for depression in managed primary care. *JAMA.* 2000;283(2):212-220.
- WHO World Health Organization. *The Global Burden of Disease: 2004 Update.* http://www.who.int/healthinfo/global_burden_disease/2004_report_update/en. Accessed December 17, 2012.